Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa/IIb study of SHR-A1904 in CLDN18.2-positive advanced biliary tract cancer after prior systemic therapy failure
CTR20260740Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garetatug rezetecan in biliary cancer, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2026; status: active.
02
Drugs
garetatug rezetecan
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20260740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260740.